Stillmind Therapeutics

A new era of therapeutic innovation begins! The FDA just approved the first antipsychotic with a novel MOA in over 20 years, bringing fresh hope for schizophrenia and future breakthroughs in psychiatric disorders.statnews.com/2024/09/26/fda… via @statnews

Today, on #WorldBipolarDay, we stand in solidarity with those living with bipolar disorder. At StillMind Tx, our commitment to pioneering precise medicines for bipolar disorder is unwavering. Let's continue to advocate for understanding, support, and groundbreaking treatments